Smith et al. reported that both anvirzel and oleandrin could inhibit the release of fibroblast growth factor-2 (FGF-2) from human prostate cancer cell lines (DU145 and PC3) in a dose and time-dependent manner. This evidence concerns the gene FGF2 and prostate cancer.